- Revvity, Inc. (RVTY, Financial) launches the IDS i20 platform, a fully automated solution for specialty assays.
- The IDS i20 can process up to 140 tests per hour across six diagnostic specialties.
- New platform offers enhanced immunodiagnostic workflows and continuous operation capabilities.
Revvity, Inc. (RVTY) has unveiled its latest innovation, the IDS i20â„¢ analytical random access platform, through its business unit EUROIMMUN. This state-of-the-art device is designed for full automation of chemiluminescence immunoassays (ChLIA), streamlining diagnostic processes in various fields including endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease, and therapeutic drug monitoring.
The IDS i20 is CE marked and FDA listed, providing labs the ability to consolidate multiple tests on a single device. It can handle 140 tests per hour, accommodating 20 different analytes from six specialties simultaneously. The platform's new software enhances adaptability, scalability, and offers a user-friendly interface that prioritizes ergonomics and cybersecurity. Its continuous loading feature for samples and reagents optimizes efficiency, allowing non-stop operation.
According to Dr. Bianca Huth, chief technical officer of EUROIMMUN, the IDS i20 platform leverages decades of expertise in laboratory automation, aiming to exceed expectations in reliability and versatility. It represents a significant step from manual and semi-automated processes to a fully automated solution, improving laboratory workflows and test throughput.
Revvity, with a revenue of over $2.7 billion in 2024 and part of the S&P 500 index, continues to revolutionize healthcare innovations across pharmaceutical, biotech, diagnostics, academia, and government sectors. The company operates in more than 160 countries, influencing the global healthcare landscape with its advanced technologies and solutions.
